---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003293"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:06:14.634931+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics reports FY2021 net loss $149.3M; cash to H2 2024; pipeline milestones outlined

## Summary
- Net loss of $149.3M for 2021 ($2.93/share) vs $59.4M in 2020; R&D spend $121.3M.
- Cash, equivalents and securities $376.6M at Dec 31, 2021; cash runway into second half 2024.
- FDA response for DYNE-251 IND in DMD expected Q2 2022; patient dosing in Phase 1/2 planned mid-2022.
- Regulatory filings for DYNE-101 in DM1 in multiple countries planned Q2 2022 with mid-2022 trial start.
- IND for DYNE-301 in FSHD expected in second half of 2022; board appointment of Carlo Incerti, M.D.

## SEC filing metadata
- accession: 0000950170-22-003293
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017022003293/0000950170-22-003293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017022003293/dyn-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003293
- JSON: https://secwatch.observer/filing/0000950170-22-003293.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.